Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$22.84M+247.46%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Glendon E. French
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 296
- Beta
- 0.28
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -5.74
Financials
Revenue
$22.84M+247.5%Net Income
$-8.39MEBITDA
$-6.79MFree Cash Flow
$-3.19MEPS (diluted)
$-0.19Shares Outstanding (diluted)
43.18M+2426.2%Operating Expenses
$24.89MCash & Debt
$52.69MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $90.50M | $-54.00M | $-1.33 |
| 2024 | $83.79M | $-56.39M | $-1.44 |
| 2023 | $68.67M | $-60.84M | $-1.60 |
| 2022 | $53.66M | $-58.92M | $-1.59 |
| 2021 | $48.42M | $-48.66M | $-1.35 |
| 2020 | $32.73M | $-32.23M | $-0.90 |
| 2019 | $32.59M | $-20.70M | $-0.58 |
| 2018 | $20.00M | $-18.48M | $-0.89 |
Valuation
LUNGhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-57.14%Social Signal Score
Mentions (14)
- Newsglobenewswire.com·4d ago·Negative
Pulmonx to Participate in the Piper Sandler 38th Annual Healthcare Conference REDWOOD CITY, Calif., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside discussion at the Piper Sandler 38th Annual Healthcare Conference in New York City on Wednesday, December 2, 2026, at 1:30 PM PT / 4:30 PM ET. The company will also be hosting in-pe…
View source ↗ - Newsglobenewswire.com·5d ago·Neutral
Pulmonx Announces Publication of CONVERT Trial Results for AeriSeal® System Pulmonx® announced the publication of CONVERT Trial results evaluating the AeriSeal® System in patients with severe emphysema and collateral ventilation.
View source ↗ - Newsfool.com·14d ago·Positive
Pulmonx: 3 Key Takeaways for Long-Term Investors Pulmonx returned to top-line growth with $22.8 million in third-quarter revenue. Third-quarter operating expenses fell 18% year over year to $24.9 million.
View source ↗ - Newszacks.com·23d ago·Positive
All You Need to Know About Pulmonx (LUNG) Rating Upgrade to Buy Pulmonx (LUNG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - Newszacks.com·26d ago·Negative
Pulmonx Corporation (LUNG) Reports Q3 Loss, Tops Revenue Estimates Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.34 per share a year ago.
View source ↗ - Newsmarketbeat.com·26d ago·Negative
What Pulmonx (LUNG) Said on Its Q3 Earnings Call Pulmonx NASDAQ: LUNG reported third-quarter revenue growth and a narrower loss as the company cited progress in rebuilding its U.S. sales organization, tightening expenses and advancing clinical programs intended to expand its market.
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Pulmonx Corporation (LUNG) Q3 2026 Earnings Call Transcript Pulmonx Corporation (LUNG) Q3 2026 Earnings Call Transcript
View source ↗ - Newsglobenewswire.com·26d ago·Negative
Pulmonx Reports Third Quarter 2026 Financial Results REDWOOD CITY, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the third quarter of 2026 ended September 30, 2026.
View source ↗ - Newsglobenewswire.com·40d ago·Negative
Pulmonx to Report Third Quarter 2026 Financial Results on October 27, 2026 REDWOOD CITY, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2026 after the close of trading on Tuesday, October 27, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m…
View source ↗ - Newsglobenewswire.com·82d ago·Negative
…nx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on September 1, 2026 (the “Grant Date”), Pulmonx granted equity awards under its 2025 Inducement Plan (the “Inducement Plan”) to four individuals hired by Pulmonx in the third fiscal quarter of 2026. The awards…
View source ↗ - Newsglobenewswire.com·87d ago·Negative
Pulmonx to Participate in Upcoming Investor Conferences REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced that management will participate in the following upcoming investor conferences:
View source ↗ - Newszacks.com·88d ago·Positive
Pulmonx Corporation (LUNG) Now Trades Above Golden Cross: Time to Buy? After reaching an important support level, Pulmonx Corporation (LUNG) could be a good stock pick from a technical perspective. LUNG recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
View source ↗ - Newsmarketbeat.com·99d ago·Neutral
Pulmonx Rebuilds Sales Force, Targets Growth and AeriSeal Launch Next Year Pulmonx NASDAQ: LUNG is rebuilding its sales organization, targeting a return to growth and preparing for potential commercialization of its AeriSeal therapy outside the United States in the second half of next year, President and CEO Glen French said during a Canaccord fireside chat.
View source ↗ - Newszacks.com·100d ago·Positive
What Makes Pulmonx Corporation (LUNG) a Strong Momentum Stock: Buy Now? Does Pulmonx Corporation (LUNG) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗
Earnings
Wed, Mar 3(in 3 months)
Consensus estimate $-0.23 per share
Typical surprise +14.3% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Oct 27$-0.19 vs $-0.26beat
- Wed, Jul 29$-0.24 vs $-0.28beat
- Wed, Apr 29$-0.33 vs $-0.33beat
- Wed, Mar 4$-0.25 vs $-0.39beat
- Wed, Nov 12$-0.34 vs $-0.40beat
- Wed, Jul 30$-0.38 vs $-0.40beat
Estimates and results for LUNG via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by LUNG officers and directors.
- Bought
- $71k
- Sold
- $854k
1 trade
69 trades
- French Glendon E. Iiisold
- French Glendon E. Iiisold
- Radhakrishnan Srikanthsold
- Radhakrishnan Srikanthsold
- Radhakrishnan Srikanthsold
- Radhakrishnan Srikanthsold
- Lehman David Aaronsold
- Lehman David Aaronsold
30 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in LUNG.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
